251 Targeting HLA-G positive tumors with engineered Natural Killer cells expressing a Chimeric ILT Receptor (CIR)

• MyLinh Duong,
• Jihyun Park,
• Raphael Ognar,
• Simon Wain-Hobson,
• Henri Bayle

Affiliations

MyLinh Duong

Department of Medicine, McMaster University, Hamilton, Ontario, Canada

Jihyun Park

NKILT Therapeutics, Houston, TX, USA

Raphael Ognar

NKILT Therapeutics, Houston, TX, USA

Simon Wain-Hobson

NKILT Therapeutics, Houston, TX, USA

Henri Bayle

NKILT Therapeutics, Houston, TX, USA